Genetic and epidemiological studies identified the inflammatory common soil between atherosclerosis and other chronic diseases, posing the rationale to introduce an anti-inflammatory approach for these chronic prevalent inflammatory diseases, such as TNF-α blockade, IL-1β receptor antagonism, and leukotriene blockade, into atherosclerosis therapy (Klingenberg and Hansson, 2009). This evidence concerns the gene TNF and atherosclerosis.